A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma
Hilty, Bailey, Ruffolo, Luis I., Belt, Brian A., Byrne, Matthew, Dave, Yatee A., Burchard, Paul R., Fisher, Terrence Lee, Evans, Elizabeth E., Mallow, Crystal L., Boise, Megan, Zauderer, Maurice, Mulkerin, Daniel, Yeh, Jen Jen, Linehan, David
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma
Ruffolo, Luis I., Fisher, Terrence Lee, Evans, Elizabeth E., Mallow, Crystal L., Boise, Megan, Foster, Amber, Leonard, John E., Belt, Brian A., Yeh, Jen Jen, Zauderer, Maurice, Linehan, David, Mulkerin, Daniel
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study
Fisher, Terrence L, Evans, Elizabeth E, Boise, Megan, Foster, Amber, Mishra, Vikas, Mallow, Crystal L, Smith, Ernest S, Leonard, John E, Feigin, Andrew, Siemers, Eric, Walters, Kimberly, Sheldon, Elizabeth, Turner, Scott, Farlow, Martin R., Zauderer, Maurice
Published in Alzheimer's & dementia (01.06.2023)
Published in Alzheimer's & dementia (01.06.2023)
Get full text
Journal Article
Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84)
Fisher, Terrence Lee, Evans, Elizabeth E., Mallow, Crystal L., Foster, Amber, Boise, Megan, Smith, Ernest, Leonard, John E., Chaney, Marya F., Beck, Joseph Thaddeus, Hager, Steven Jeffrey, Mekhail, Tarek, Seetharamu, Nagashree, Baumgart, Megan, Saba, Nabil F., Steuer, Conor Ernst, Adkins, Douglas, Burtness, Barbara, Zauderer, Maurice
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Abstract A004: A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinoma
Ruffolo, Luis I, Byrne, Matthew, Hilty, Bailey, Belt, Brian A, Dave, Yatee, Burchard, Paul, Fisher, Terrence, Evans, Elizabeth E., Mallow, Crystal, Boise, Megan, Carpizo, Darren, Yeh, Jen Jen, Linehan, David C, Mulkerin, Daniel
Published in Cancer research (Chicago, Ill.) (15.09.2024)
Published in Cancer research (Chicago, Ill.) (15.09.2024)
Get full text
Journal Article
Abstract CT111: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84)
Fisher, Terrence L., Evans, Elizabeth E., Mallow, Crystal, Foster, Amber, Boise, Megan, Smith, Ernest, Leonard, John E., Chaney, Marya F., Beck, J. Thaddeus, Hager, Steven, Saba, Nabil F., Steuer, Conor, Adkins, Douglas, Burtness, Barbara, Zauderer, Maurice
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article